Home > Journals > Minerva Endocrinology > Past Issues > Articles online first > Minerva Endocrinology 2021 Apr 01

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Endocrinology 2021 Apr 01

DOI: 10.23736/S2724-6507.21.03391-5

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Subclinical thyroid diseases and isolated hypothyroxinemia during pregnancy

Pietro LOCANTORE , Andrea CORSELLO, Caterina POLICOLA, Alfredo PONTECORVI

Unit of Endocrinology, Fondazione Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy


PDF


INTRODUCION: Thyroid diseases in pregnancy are common. While data on management of overt diseases are clear, there is no consensus regarding subclinical thyroid disease. Many studies have tried to clarify the impact of subclinical thyroid disease on pregnancy outcomes without reaching universal conclusions.
EVIDENCE ACQUISITION: As several studies are present in literature, but no univocal indication is present to manage each condition, the present review tries to summarize the recent indications for such disease. The most updated guidelines are 2017 American thyroid association for of thyroid disease during pregnancy, which at present represent the most accurate and reliable guide.
EVIDENCE SYNTHESIS: Subclinical hyperthyroidism during pregnancy has not been associated with adverse outcomes and only needs follow up. Subclinical hypothyroidism is associated with adverse obstetric and offspring outcomes. At present thyroxine treatment is recommended in selected cases, as beneficial effects are not clear for all these patients. Data regarding the association between isolated hypothyroxinemia and adverse meternofetal outcome are controversial but treatment is not indicated. Autoimmune thyroid disease represents the main thyroid risk factor for adverse pregnancy outcomes. If patients have normal TSH values, treatment is not indicated. A possible thyroxine treatment can be evaluated on a case-by-case basis in euthyroid patients with history of abortion/infertility.
CONCLUSIONS: In the last years, risks of subclinical thyroid dysfunction on the outcome of gestation and newborn have been scaled back. Further prospective studies are necessary to better understand thyroid dysfunction in pregnancy to perfectly target treatment in appropriate settings.


KEY WORDS: Subclinical thyroid disease; Hypothyroidism; Isolated hypothyroxinemia; Gestational transient thyrotoxicosis; Pregnancy

top of page